2 days ago
2
Soumya Eswaran
Thu, June 18, 2026 astatine 8:54 AM CDT 3 min read
Prosper Stars & Stripes, a long/short equity fund, precocious released its first-quarter 2026 capitalist letter. A transcript of the missive is disposable to download here. In Q1 2026, the portfolio underperformed with a nett instrumentality of (-5.6%) compared to the Russell 2000 Index's +0.9% instrumentality and the HFRX Equity Hedge Index's -1.5% return. Long publication show was negative, portion the abbreviated publication contributed positively. Geopolitics importantly influenced the archetypal quarter, contributing to accrued ostentation pressures and elevated vigor prices. Additionally, you tin reappraisal the Portfolio's apical 5 holdings to spot its champion picks for 2026.
In its first-quarter 2026 capitalist letter, Prosper Stars & Stripes highlighted BioLife Solutions, Inc. (NASDAQ:BLFS). BioLife Solutions, Inc. (NASDAQ:BLFS) is simply a biotechnology institution that develops and manufactures bioproduction products and services for the compartment and cistron therapy (CGT) industry. On June 16, 2026, BioLife Solutions, Inc. (NASDAQ:BLFS) closed astatine $25.58 per share. One-month instrumentality of BioLife Solutions, Inc. (NASDAQ:BLFS) was 3.40%, and its shares gained 18.87% implicit the past 52 weeks. BioLife Solutions, Inc. (NASDAQ:BLFS) has a marketplace capitalization of $1.29 billion.
Prosper Stars & Stripes stated the pursuing regarding BioLife Solutions, Inc. (NASDAQ:BLFS) successful its Q1 2026 capitalist letter:
"We actively show our Focus List to revisit compelling ideas erstwhile risk/reward becomes favorable. This subject drove some our determination to reinvest successful Vishay Precision and to adhd BioLife Solutions, Inc. (NASDAQ:BLFS) backmost into the portfolio. BioLife has had an eventful past arsenic a nationalist company. The company's erstwhile CEO pursued an acquisition strategy that we judge diluted alternatively than enhanced the company's halfway strengths. Current CEO Roderick de Greef has mostly reversed that course, divesting astir of those businesses and refocusing the institution connected its highest-quality products. The effect is simply a cleaner, much focused business, amended positioned to capitalize connected the underlying maturation successful its extremity markets. The cornerstone of the concern has ever been biopreservation media, a merchandise with a precocious maturation complaint and exceptional margins. This is an fantabulous illustration of a 'picks & shovel' concern successful healthcare. The media is utilized by customers successful the manufacturing of cell-based therapies, an end-market expected to turn implicit 20% annually implicit the adjacent 5 years. The caller underperformance of healthcare and beingness subject tools stocks brought BioLife's valuation to a level wherever we again spot a compelling agelong opportunity. With 20%-plus top-line maturation 13 and meaningful borderline enlargement driving accelerated EBITDA growth, we judge the banal offers a compelling risk/reward from existent levels."
.png)
English (CA) · 
English (US) · 
Spanish (MX) ·